Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAIN: Relatlimab and Nivolumab Maintenance in Nasopharyngeal Carcinoma
NCT06029270Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of relatlimab in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 6 years. Started Jul 2024; status: recruiting.
02
Drugs
relatlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06029270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029270.